FM-101 (Femta Pharmaceuticals)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameFM-101 (Femta Pharmaceuticals)
Drug Alias NameFM-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-6 inhibitors
TargetsInterleukin-6
Therapy Area/IndicationsCrohn DiseaseArthritis, RheumatoidMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesFemta Pharmaceutical
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFemta Pharmaceutical
Active IndicationsN/A
Inactive IndicationsCrohn DiseaseArthritis, RheumatoidMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksN/A